News & Updates

Intramuscular administration of single-dose AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab and cilgavimab), significantly reduced the risk of developing symptomatic COVID-19 in adults, according to the PROVENT* study presented at IDWeek 2021.

In patients with chronic plaque psoriasis, once-daily treatment with roflumilast improved severity and burden of itch compared with vehicle cream, according to results of the phase III DERMIS-1 and DERMIS-2 trials presented at EADV 2021.

Access to pre-exposure prophylaxis (PrEP) may be expanded through pharmacies to reach racial minorities of men who have sex with men (MSM) with the highest need but are not being reached, suggest the results of a US study.

The most effective nonsteroidal anti-inflammatory drugs (NSAIDs) for pain and function in patients with osteoarthritis (OA) are etoricoxib 60 mg/day and diclofenac 150 mg/day, suggests a study. However, these medications may not be suitable for those with comorbidities or for long-term use due to the slight increase in the risk of adverse events.

Cancer patients receiving either low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) show comparable frequency of venous thromboembolism (VTE), reports a recent study.

In the treatment of patients with severe, uncontrolled asthma, use of tezepelumab appears to produce rapid and sustained improvements in lung function, as reported in a study.

A 3-day course of remdesivir may help stave off COVID-19–related hospitalization and death, according to results of the phase III PINETREE study.